| Literature DB >> 33671077 |
Kaitlyn Blatt-Janmaat1, Yang Qu1,2.
Abstract
The medicinal properties of cannabis and the its legal status in several countries and jurisdictions has spurred the massive growth of the cannabis economy around the globe. The value of cannabis stems from its euphoric activity offered by the unique phytocannabinoid tetrahydrocannabinol (THC). However, this is rapidly expanding beyond THC owing to other non-psychoactive phytocannabinoids with new bioactivities that will contribute to their development into clinically useful drugs. The discovery of the biosynthesis of major phytocannabinoids has allowed the exploration of their heterologous production by synthetic biology, which may lead to the industrial production of rare phytocannabinoids or novel synthetic cannabinoid pharmaceuticals that are not easily offered by cannabis plants. This review summarizes the biosynthesis of major phytocannabinoids in detail, the most recent development of their metabolic engineering in various systems, and the engineering approaches and strategies used to increase the yield.Entities:
Keywords: FAD-dependent monooxygenase; aromatic prenyltransferase; cannabinoid biosynthesis; metabolic engineering; polyketide synthase; synthetic biology; yeast fermentation
Mesh：
Substances：
Year: 2021 PMID： 33671077 PMCID： PMC7957758 DOI： 10.3390/ijms22052454
Source DB: PubMed Journal: Int J Mol Sci ISSN： 1422-0067 Impact factor: 5.923